Assessment of the Pectolinarin (cas 134-33-8) content and the radical scavenging-linked antiobesity activity of Cirsium setidens Nakai extracts
-
Add time:09/29/2019 Source:infona.pl
Cirsium setidens Nakai contains bioactive compounds that exert biological activities. Method validation for analysis of the Pectolinarin (cas 134-33-8) content in Cirsium setidens extracts (CSE) and radical scavenging-linked antiobesity activities using 3T3-L1 cells and C57BL/6 mice were performed. The pectolinarin content of CSE was 2.81±0.01 mg/g with a high degree of linearity in calibration curves (R 2=0.9999). CSE exhibited free radical-scavenging activities and a reducing power. CSE and pectolinarin inhibited lipid accumulation during adipogenesis of 3T3-L1 cells via down-regulation of adipogenic transcription factors. CSE supplementation suppressed body weight in C57BL/6 mice fed a high fat diet and reduced plasma total cholesterol, triglyceride, insulin, and glucose levels. Pectolinarin-enriched CSE can be considered as a good source of natural antioxidants and antiobesity ingredients.
We also recommend Trading Suppliers and Manufacturers of Pectolinarin (cas 134-33-8). Pls Click Website Link as below: cas 134-33-8 suppliers
Prev:Pectolinarigenin, an aglycone of Pectolinarin (cas 134-33-8), has more potent inhibitory activities on melanogenesis than Pectolinarin (cas 134-33-8)
Next:Pectolinarin (cas 134-33-8) inhibits proliferation, induces apoptosis, and suppresses inflammation in rheumatoid arthritis fibroblast‐like synoviocytes by inactivating the phosphatidylinositol 3 kinase/protein kinase B pathway) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Pectolinarin (cas 134-33-8) inhibits proliferation, induces apoptosis, and suppresses inflammation in rheumatoid arthritis fibroblast‐like synoviocytes by inactivating the phosphatidylinositol 3 kinase/protein kinase B pathway09/30/2019
- Pectolinarigenin, an aglycone of Pectolinarin (cas 134-33-8), has more potent inhibitory activities on melanogenesis than Pectolinarin (cas 134-33-8)10/01/2019